Table 3.
Adjusted models for the association between HT use and new-onset depressive symptoms after 4-year follow-up, among women without depression at baseline.
| HT use at baselinea (n) | Depressive symptoms (%) | ORb [95% CI] | p-value |
|---|---|---|---|
| Never (2072) | 17.13 | 1.0 | |
| Current (470) | 18.38 | 1.35 [1.00–1.83] | 0.06 |
| Never (n=2072) | 17.13 | 1.0 | |
| Unopposed transdermal (n=80) | 16.25 | 1.06 [0.56–2.03] | 0.85 |
| Unopposed oral (n=9) | 11.11 | 0.95 [0.11–7.85] | 0.96 |
| Opposed transdermal (n=292) | 19.18 | 1.48 [1.03–2.12] | 0.03 |
| - with progesterone (n=134) | 18.66 | 1.36 [0.82–2.26] | 0.24 |
| - with synthetic progestin (n=158) | 19.62 | 1.59 [1.01–2.50] | 0.046 |
| Opposed oral (n=79) | 20.25 | 1.47 [0.78–2.77] | 0.23 |
| - with progesterone (n=13) | 23.08 | 1.90 [0.51–7.07] | 0.34 |
| - with synthetic progestin (n=66) | 19.70 | 1.38 [0.68–2.81] | 0.37 |
| Other unrelated HT types (n=10) | nd | nd | nd |
a
Corresponds to opposed and unopposed estradiol-based HT.
b
Adjusted for age, educational level, centre, widowhood, age at menopause, insomnia, disability, cognitive impairment, chronic health disorders and history of depression.
Abbreviation: HT: Hormonal Therapy; nd: not determined.